Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) just unveiled an announcement.
Shin Nippon Biomedical Laboratories, Ltd. announced a year-end dividend payment of ¥30.00 per share for the fiscal year ended March 31, 2025, resulting in an annual dividend of ¥50.00 per share. This decision reflects the company’s solid performance in its CRO business, despite increased expenses from the FDA approval of Satsuma’s STS101, and aligns with its policy of stable profit distribution.
The most recent analyst rating on (JP:2395) stock is a Hold with a Yen1460.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the biomedical industry, focusing on contract research organization (CRO) services. The company is committed to providing stable profit distributions to shareholders and aims for a payout ratio of 30-40% on a consolidated basis.
Average Trading Volume: 405,215
Technical Sentiment Signal: Sell
Current Market Cap: Yen55.75B
For a thorough assessment of 2395 stock, go to TipRanks’ Stock Analysis page.